European Thyroid Journal
Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients
By Juan J Díez, Emma Anda, Victoria Alcazar and 7 others.
Abstract
Background
Levothyroxine titration is essential in low-risk differentiated thyroid cancer (DTC).
Objective
To compare levothyroxine treatment adequacy, response distribution, and determinants of inadequacy in a large real-world cohort applying the 2015 versus 2025 American Thyroid Association (ATA) criteria.
